Aligos Therapeutics
ALGS
35 hedge funds and large institutions have $20.6M invested in Aligos Therapeutics in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 10 closing their positions.
5.82% more ownership
Funds ownership: 45.68% → 51.51% (+5.8%)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
13% less funds holding
Funds holding: 40 → 35 (-5)
21% less capital invested
Capital invested by funds: $26.2M → $20.6M (-$5.58M)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$1.64M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$278K |
| 3 |
Renaissance Technologies
New York
|
+$114K |
| 4 |
D.E. Shaw & Co
New York
|
+$83.3K |
| 5 |
QC
Quadrature Capital
London,
United Kingdom
|
+$82.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$848K |
| 2 |
Two Sigma Investments
New York
|
-$437K |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$397K |
| 4 |
Jane Street
New York
|
-$226K |
| 5 |
DS
DRW Securities
Chicago,
Illinois
|
-$111K |
ALGS Hedge Fund Activity: Q1 2026 in Review
35 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q1 2026, worth a combined $20.6M — down 21% from $26.2M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ALGS and 7 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 8 added.
The largest buyer was Bank of America, adding an estimated $1.64M. The largest seller was Woodline Partners, cutting an estimated $848K.
- 35 institutional investors held Aligos Therapeutics (ALGS) as of Q1 2026, down from 40 in Q4 2025.
- Funds reported $20.6M of Aligos Therapeutics stock for Q1 2026, down 21% quarter-over-quarter.
- 7 funds opened new Aligos Therapeutics positions in Q1 2026 and 10 closed out, a net change of -3 holders.
- The largest Aligos Therapeutics buyer in Q1 2026 was Bank of America, an estimated $1.64M added.
- The largest Aligos Therapeutics seller in Q1 2026 was Woodline Partners, an estimated $848K sold.
Based on aggregated 13F filings for Q1 2026.